Cargando…

An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical...

Descripción completa

Detalles Bibliográficos
Autores principales: Momtahen, Shadi, Momtahen, Maryam, Ramaseshan, Ramani, Golnaraghi, Farid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303311/
https://www.ncbi.nlm.nih.gov/pubmed/37420927
http://dx.doi.org/10.3390/s23125761
_version_ 1785065248200327168
author Momtahen, Shadi
Momtahen, Maryam
Ramaseshan, Ramani
Golnaraghi, Farid
author_facet Momtahen, Shadi
Momtahen, Maryam
Ramaseshan, Ramani
Golnaraghi, Farid
author_sort Momtahen, Shadi
collection PubMed
description Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical biosensor called the Opti-scan probe to assess residual cancer burden in breast cancer patients undergoing NAC. The Opti-scan probe data were acquired from 15 patients (mean age: 61.8 years) before and after each cycle of NAC. Using regression analysis with k-fold cross-validation, we calculated the optical properties of healthy and unhealthy breast tissues. The ML predictive model was trained on the optical parameter values and breast cancer imaging features obtained from the Opti-scan probe data to calculate RCB values. The results show that the ML model achieved a high accuracy of 0.98 in predicting RCB number/class based on the changes in optical properties measured by the Opti-scan probe. These findings suggest that our ML-based Opti-scan probe has considerable potential as a valuable tool for the assessment of breast cancer response after NAC and to guide treatment decisions. Therefore, it could be a promising, non-invasive, and accurate method for monitoring breast cancer patient’s response to NAC.
format Online
Article
Text
id pubmed-10303311
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103033112023-06-29 An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Momtahen, Shadi Momtahen, Maryam Ramaseshan, Ramani Golnaraghi, Farid Sensors (Basel) Article Breast cancer patients undergoing neoadjuvant chemotherapy (NAC) require precise and accurate evaluation of treatment response. Residual cancer burden (RCB) is a prognostic tool widely used to estimate survival outcomes in breast cancer. In this study, we introduced a machine-learning-based optical biosensor called the Opti-scan probe to assess residual cancer burden in breast cancer patients undergoing NAC. The Opti-scan probe data were acquired from 15 patients (mean age: 61.8 years) before and after each cycle of NAC. Using regression analysis with k-fold cross-validation, we calculated the optical properties of healthy and unhealthy breast tissues. The ML predictive model was trained on the optical parameter values and breast cancer imaging features obtained from the Opti-scan probe data to calculate RCB values. The results show that the ML model achieved a high accuracy of 0.98 in predicting RCB number/class based on the changes in optical properties measured by the Opti-scan probe. These findings suggest that our ML-based Opti-scan probe has considerable potential as a valuable tool for the assessment of breast cancer response after NAC and to guide treatment decisions. Therefore, it could be a promising, non-invasive, and accurate method for monitoring breast cancer patient’s response to NAC. MDPI 2023-06-20 /pmc/articles/PMC10303311/ /pubmed/37420927 http://dx.doi.org/10.3390/s23125761 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Momtahen, Shadi
Momtahen, Maryam
Ramaseshan, Ramani
Golnaraghi, Farid
An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_full An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_fullStr An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_full_unstemmed An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_short An Optical Sensory System for Assessment of Residual Cancer Burden in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
title_sort optical sensory system for assessment of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303311/
https://www.ncbi.nlm.nih.gov/pubmed/37420927
http://dx.doi.org/10.3390/s23125761
work_keys_str_mv AT momtahenshadi anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT momtahenmaryam anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT ramaseshanramani anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT golnaraghifarid anopticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT momtahenshadi opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT momtahenmaryam opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT ramaseshanramani opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy
AT golnaraghifarid opticalsensorysystemforassessmentofresidualcancerburdeninbreastcancerpatientsundergoingneoadjuvantchemotherapy